New research has discovered that patients with prostate cancer have lower vitamin D levels compared to patients with benign prostatic hyperplasia.
Multiple studies have shown a link between vitamin D levels and prostate cancer with a study reporting that men with prostate cancer who had the lowest vitamin D levels were less likely to survive compared to men who had higher vitamin D levels.
In a recent study, researchers from Poland compared the vitamin D levels between 30 men with prostate cancer and 30 men with benign prostatic hyperplasia (BPH). BPH is a condition in which the prostate gland is enlarged and not cancerous.
The researchers wanted to determine whether low vitamin D levels were associated with an increased risk of prostate cancer. They found that the patients with prostate cancer were vitamin D deficient, with a median vitamin D status of 25.3 ng/ml; whereas patients with BPH had a median vitamin D level of 34.8 ng/ml.
The researchers concluded, “Vitamin D concentration in Polish men with prostate cancer is lower compared to patients with benign prostatic hyperplasia.”
Wieczorek K. et al. “The comparison between vitamin d concentration in upper silesia patients with prostate cancer and with benign prostatic hyperplasia.” Journal of biological regulators and homeostatic agents, 2015.